This brand name is authorized in Australia, Austria, Brazil, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Mexico, Netherlands, New Zealand, Nigeria, Poland, Romania, Singapore, Spain, Tunisia, Turkey, UK.
The drug CETROTIDE contains one active pharmaceutical ingredient (API):
1
|
UNII
W9Y8L7GP4C - CETRORELIX ACETATE
|
|
Cetrorelix is a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity. GnRH induces the production and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the gonadotrophic cells of the anterior pituitary. Due to a positive estradiol (E2) feedback at midcycle, GnRH liberation is enhanced resulting in an LH-surge. This LH-surge induces the ovulation of the dominant follicle, resumption of oocyte meiosis and subsequently luteinization as indicated by rising progesterone levels. Cetrorelix competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner. Cetrorelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion. It competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner. Cetrotide (cetrorelix acetate for injection) is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation. |
|
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| CETROTIDE Powder and solvent for solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| H01CC02 | Cetrorelix | H Systemic hormonal preparations, excl. Sex hormones and insulins → H01 Pituitary and hypothalamic hormones and analogues → H01C Hypothalamic hormones → H01CC Anti-gonadotropin-releasing hormones |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| AU | Pharmaceutical Benefits Scheme | 9599F |
| BR | Câmara de Regulação do Mercado de Medicamentos | 525421701150311 |
| EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | 29034-09-09 |
| EE | Ravimiamet | 1043356, 1043367, 1064696 |
| ES | Centro de información online de medicamentos de la AEMPS | 99100001, 99100002 |
| FI | Lääkealan turvallisuus- ja kehittämiskeskus | 005766 |
| FR | Base de données publique des médicaments | 60650426 |
| GB | Medicines & Healthcare Products Regulatory Agency | 41575 |
| HK | Department of Health Drug Office | 46953 |
| IE | Health Products Regulatory Authority | 88452, 88819 |
| IL | מִשְׂרַד הַבְּרִיאוּת | 4054 |
| JP | 医薬品医療機器総合機構 | 2499421D1023 |
| LT | Valstybinė vaistų kontrolės tarnyba | 1006177, 1006178 |
| MX | Comisión Federal para la Protección contra Riesgos Sanitarios | 519M2001 |
| NG | Registered Drug Product Database | B4-8486 |
| NL | Z-Index G-Standaard | 14639580 |
| NL | Z-Index G-Standaard, PRK | 52795 |
| NZ | Medicines and Medical Devices Safety Authority | 8400 |
| PL | Rejestru Produktów Leczniczych | 100094481 |
| RO | Agenția Națională a Medicamentului și a Dispozitivelor Medicale | W65132001, W65132002 |
| SG | Health Sciences Authority | 11345P |
| TN | Direction de la Pharmacie et du Médicament | 22073051, 4703021, 4703022 |
| TR | İlaç ve Tıbbi Cihaz Kurumu | 8699777790225, 8699777790232 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.